Longitudinal assessment of antimicrobial susceptibility among gram-negative and gram-positive organisms collected from Italy as part of the Tigecycline evaluation and surveillance trial between 2004 and 2011

Pharmaceuticals

Volumn 6, Issue 11, 2013, Pages 1381-1406

  Stefani, Stefania ^a   Dowzicky, Michael J ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b PFIZER INC   (United States)

Author keywords

Antimicrobial resistance; Italy; Surveillance; Tigecycline

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METICILLIN; MINOCYCLINE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG MONITORING; DRUG SCREENING; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; ITALY; LONGITUDINAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; PSEUDOMONAS AERUGINOSA; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 84887358963     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph6111381     Document Type: Article

References (38)

1. European Centre for Disease Prevention and Control (ECDC). Antimicrobial Resistance Surveillance in Europe 2011. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). ECDC: Stockholm, Sweden, 2012.
2. Pankey, G.A. Tigecycline. J. Antimicrob. Chemother. 2005, 56, 470-480.
3. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard, 8th ed.; Document M7-A8; Wayne, PA, USA, 2009.
4. Guthrie, L.L.; Banks, S.; Setiawan, W.; Waites, K.B. Comparison of MicroScan MICroSTREP, PASCO, and Sensititre MIC panels for determining antimicrobial susceptibilities of Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 1999, 33, 267-273.
5. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 23rd ed.; Document M100-S23; Wayne, PA, USA, 2013.
6. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 20th ed. (June 2010 update); Document M100-S20U; Wayne, PA, USA, 2010.
7. Wyeth Pharmaceuticals, Pfizer Inc. Tygacil® Product Insert. Available online: http://www.pfizerpro.com/hcp/tygacil (accessed 15 November 2012).
8. Manchanda, V.; Sanchaita, S.; Singh, N.P. Multidrug Resistant Acinetobacter. J. Global Infect. Dis. 2010, 2, 291-304.
9. Falagas, M.E.; Koletsi, P.K.; Bliziotis, I.A. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med. Microbiol. 2006, 55, 1619-1629.
10. Magiorakos, A.P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012, 18, 268-281.
11. Bassetti, M.; Nicolini, L.; Repetto, E.; Righi, E.; del Bono, V.; Viscoli, C. Tigecycline use in serious nosocomial infections: A drug use evaluation. BMC Infect. Dis. 2010, 10, 287.
12. Mezzatesta, M.L.; Trovato, G.; Gona, F.; Nicolosi, V.M.; Nicolosi, D.; Carattoli, A.; Fadda, G.; Nicoletti, G.; Stefani, S. In vitro activity of tigecycline and comparators against carbapenemsusceptible and resistant Acinetobacter baumannii clinical isolates in Italy. Ann. Clin. Microbiol. Antimicrob. 2008, 7, 4.
13. Lambiase, A.; Piazza, O.; Rossano, F.; Del Pezzo, M.; Tufano, R.; Catania, M.R. Persistence of carbapenem-resistant Acinetobacter baumannii strains in an Italian intensive care unit during a forty-six month study period. New Microbiol. 2012, 35, 199-206.
14. D'Arezzo, S.; Principe, L.; Capone, A.; Petrosillo, N.; Petrucca, A.; Visca, P. Changing carbapenemase gene pattern in an epidemic multidrug-resistant Acinetobacter baumannii lineage causing multiple outbreaks in central Italy. J. Antimicrob. Chemother. 2011, 66, 54-61.
15. Donnarumma, F.; Sergi, S.; Indorato, C.; Mastromei, G.; Monnanni, R.; Nicoletti, P.; Pecile, P.; Cecconi, D.; Mannino, R.; Bencini, S.; et al. Molecular characterization of Acinetobacter isolates collected in intensive care units of six hospitals in Florence, Italy, during a 3-year surveillance program: A population structure analysis. J. Clin. Microbiol. 2010, 48, 1297-1304.
16. Zarrilli, R.; Pournaras, S.; Giannouli, M.; Tsakris, A. Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. Int. J. Antimicrob. Agents 2013, 41, 11-19.
17. Principe, L.; D'Arezzo, S.; Capone, A.; Petrosillo, N.; Visca, P. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann. Clin. Microbiol. Antimicrob. 2009, 8, 18.
18. Ricciardi, R.; Ricciardi, A.M.; Danzi, G. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii clinical isolates. Infez. Med. 2009, 17, 236-239.
19. European Centre for Disease Prevention and Control (ECDC). Antimicrobial Resistance Surveillance in Europe 2010. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net); ECDC: Stockholm, Sweden, 2011.
20. Spanu, T.; Luzzaro, F.; Perilli, M.; Amicosante, G.; Toniolo, A.; Fadda, G.; Italian ESBL Study Group. Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: Implications for resistance to beta-lactams and other antimicrobial drugs. Antimicrob. Agents Chemother. 2002, 46, 196-202.
21. Manfredi, R.; Nanetti, A. An active microbiological surveillance project at an Italian teaching hospital: Microbial isolates, recent epidemiological trends, major clinical concerns, and antimicrobial susceptibility rates during a four-year period. Infez. Med. 2009, 17, 219-227.
22. D'Errico, M.M.; Marigliano, A.; Pellegrini, I.; Gioia, M.G.; Savini, S.; Gigli, M.; Martini, E.; Manso, E.; Barbadoro, P. Reporting of a surveillance system of multidrug-resistantorganisms in an Italian hospital. BMC Proc. 2011, 5(Suppl. 6), P298.
23. Paterson, D.L.; Bonomo, R.A. Extended-spectrum beta-lactamases: A clinical update. Clin. Microbiol. Rev. 2005, 18, 657-686.
24. De Kraker, M.E.; Wolkewitz, M.; Davey, P.G.; Koller, W.; Berger, J.; Nagler, J.; Icket, C.; Kalenic, S.; Horvatic, J.; Seifert, H.; et al. Burden of antimicrobial resistance in European hospitals: Excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J. Antimicrob. Chemother. 2011, 66, 398-407.
25. Martínez-Martínez, L. Extended-spectrum beta-lactamases and the permeability barrier. Clin. Microbiol. Infect. 2008, 14(Suppl. 1), 82-89.
26. Sisto, A.; D'Ancona, F.; Meledandri, M.; Pantosti, A.; Rossolini, G.M.; Raglio, A.; Serra, R.; Dematte, L.; Aiello, E.; Goglio, A.; Micronet network participants. Carbapenem non-susceptible Klebsiella pneumoniae from Micronet network hospitals, Italy, 2009 to 2012. Euro Surveill. 2012, 17, 20247.
27. Fontana, R.; Ligozzi, M.; Mazzariol, A.; Veneri, G.; Cornaglia, G. Resistance of enterococci to ampicillin and glycopeptide antibiotics in Italy. The Italian Surveillance Group for Antimicrobial Resistance. Clin. Infect. Dis. 1998, 27, S84-S86.
28. Montecalvo, M.A.; Jarvis, W.R.; Uman, J.; Shay, D.K.; Petrullo, C.; Rodney, K.; Gedris, C.; Horowitz, H.W.; Wormser, G.P. Infection-control measures reduce transmission of vancomycinresistant enterococci in an endemic setting. Ann. Intern. Med. 1999, 131, 269-272.
29. Crivellaro, S.; Leone, I.; Bianco, O.; Savoia, D. Surveillance of methicillin-resistant Staphylococcus aureus isolated in Torino (northwest Italy). Diag. Microbiol. Infect. Dis. 2011, 69, 250-257.
30. Gagliotti, C.; Monaco, M.; Sabia, C.; Gargiulo, R.; Sarti, M.; Sanchini, A.; Marchi, M.; Ambretti, S.; Calanca, F.; Carillo, C.; et al. Staphylococcus aureus in a northern Italian region: Phenotypic and molecular characterization. Scand. J. Infect. Dis. 2012, 44, 24-28.
31. Aschbacher, R.; Pichon, B.; Spoladore, G.; Pagani, E.; Innocenti, P.; Moroder, L.; Ganner, M.; Hill, R.; Pike, R.; Ganthaler, O.; et al. High clonal heterogeneity of Panton-Valentine leukocidinpositive meticillin-resistant Staphylococcus aureus strains from skin and soft-tissue infections in the Province of Bolzano, Northern Italy. Int. J. Antimicrob. Agents 2012, 39, 522-525.
32. Di Giacobbe, A.; Pecetta, S.; Virga, A.; Scazzocchio, F.; Aquilanti, L.; Iebba, V.; Passariello, C. Diffusion of meticillin-resistant Staphylococcus aureus USA300 strains in central Italy. Int. J. Antimicrob. Agents 2011, 37, 339-346.
33. Dhand, A.; Sakoulas, G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ("the MIC Creep"): Implications for therapy. F1000 Med. Rep. 2012, 4, 4.
34. Joana, S.; Pedro, P.; Elsa, G.; Filomena, M. Is vancomycin MIC creep a worldwide phenomenon? Assessment of S. aureus vancomycin MIC in a tertiary university hospital. BMC Res. Notes 2013, 6, 65.
35. Campanile, F.; Borbone, S.; Perez, M.; Bongiorno, D.; Cafiso, V.; Bertuccio, T.; Purrello, S.; Nicolosi, D.; Scuderi, C.; Stefani, S. Heteroresistance to glycopeptides in Italian meticillin-resistant Staphylococcus aureus (MRSA) isolates. Int. J. Antimicrob. Agents 2010, 36, 415-419.
36. Pfizer Inc. T.E.S.T. Study Online. Available online: www.testsurveillance.com (accessed on 22 October 2013).
37. Weinstein, R.A. Controlling antimicrobial resistance in hospitals: Infection control and use of antibiotics. Emerg. Infect. Dis. 2001, 7, 188-192.
38. MacDougall, C.; Polk, R.E. Antimicrobial Stewardship Programs in Health Care Systems. Clin. Microbiol. Rev. 2005, 18, 638-656.